The Early Phase of β2-Microglobulin Aggregation: Perspectives From Molecular Simulations
Related Experiment Video
Updated: Dec 2, 2025
Characterizing Individual Protein Aggregates by Infrared Nanospectroscopy and Atomic Force Microscopy
Published on: September 12, 2019
Rui J S Loureiro1, Patrícia F N Faísca1,2
1Faculty of Sciences, BioISI - Biosystems & Integrative Sciences Institute, University of Lisboa, Lisbon, Portugal.
Abstract:
Protein β2-microglobulin is the causing agent of two amyloidosis, dialysis related amyloidosis (DRA), affecting the bones and cartilages of individuals with chronic renal failure undergoing long-term hemodialysis, and a systemic amyloidosis, found in one French family, which impairs visceral organs. The protein's small size and its biomedical significance attracted the attention of theoretical scientists, and there are now several studies addressing its aggregation mechanism in the context of molecular simulations. Here, we review the early phase of β2-microglobulin aggregation, by focusing on the identification and structural characterization of monomers with the ability to trigger aggregation, and initial small oligomers (dimers, tetramers, hexamers etc.) formed in the so-called nucleation phase. We focus our analysis on results from molecular simulations and integrate our views with those coming from in vitro experiments to provide a broader perspective of this interesting field of research. We also outline directions for future computer simulation studies.
Insights
Protein β2-microglobulin aggregation initiates dialysis-related amyloidosis (DRA) and systemic amyloidosis. This review details early aggregation phases, focusing on critical monomers and oligomers identified via molecular simulations and in vitro studies.
Area of Science:
- Biochemistry
- Biophysics
- Computational Biology
Background:
- Protein β2-microglobulin (β2M) causes dialysis-related amyloidosis (DRA) and systemic amyloidosis.
- The aggregation mechanism of β2M is of significant interest due to its biomedical implications.
Purpose of the Study:
- To review the early stages of β2M aggregation.
- To identify and structurally characterize aggregation-prone monomers and early oligomers.
- To integrate findings from molecular simulations and in vitro experiments.
Main Methods:
- Review of molecular simulation studies on β2M aggregation.
- Analysis of in vitro experimental data on β2M aggregation.
- Focus on the nucleation phase of β2M aggregation.
Main Results:
- Identification of specific β2M monomer structures that initiate aggregation.
- Characterization of initial small oligomers (dimers, tetramers, hexamers) in the nucleation phase.
- Integration of computational and experimental data provides a comprehensive view of early aggregation.
Conclusions:
- Understanding the early phase of β2M aggregation is crucial for comprehending amyloidosis pathogenesis.
- Molecular simulations are powerful tools for investigating protein aggregation mechanisms.
- Future simulations should further explore the dynamics of β2M aggregation and oligomerization.
